跳至主要内容
临床试验/TCTR20220526003
TCTR20220526003Unknown3 期

Immunogenicity of a single standard dose versus a double standard dose of inactivated trivalent influenza vaccine in patients on peritoneal dialysis: Open labelled Randomized control trial

Health Systems Research Institute(HSRI)0 个研究点目标入组 125 人开始时间: 2022年5月26日最近更新:
适应症

试验速览

阶段
3 期
发起方
入组人数
125

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
All

入选标准

  • 1. End stage kidney disease patients on peritoneal dialysis more than one month with a total weekly kt/v of at least 1.7
  • 2. Life expectancy more than 1 year
  • 3. No history of kidney transplantation

排除标准

  • 1. Receiving any vaccine 2 weeks before enrollment
  • 2. Receiving influenza vaccine 6 months before enrollment
  • 3. Egg allergy, influenza vaccine allergy
  • 4. influenza-like symptoms in the previous 3 days
  • 5. thrombocytopenia
  • 6. recieved immunosuppression or having immunocompromised status
  • 7. active cancer with treatment
  • 8. underwent organ transplantation
  • 9. history of Guillain-Barre syndrome or family history of Guillain-Barre syndrome

研究者

发起方
Health Systems Research Institute(HSRI)

相似试验